[Médecins Sans Frontières Access Campaign] The European Union’s (EU) free trade and research and development (R&D) policies promote excessive intellectual property (IP) protection. This approach jeopardises access to affordable, needed medicines and impedes needs-driven biomedical innovation. Médecins Sans Frontières Access Campaign and our partners at HAI Europe and Oxfam are offering policy-makers seven straight-forward solutions that could transform harmful trade and R&D policy. By taking these solutions on board, the EU could enhance medicines access and pharmaceutical innovation in the EU and around the world.
Follow
Free to Share
Comments on:
- An error has occurred, which probably means the feed is down. Try again later.
Civil Society Documents
- An error has occurred, which probably means the feed is down. Try again later.
Comments on:
- An error has occurred, which probably means the feed is down. Try again later.
industry | infojustice
- Aspen Doesn’t Want You to Own Your Own Casebooks
- Still Profitable After All These Years
- Recording Industry Reports Growth from User-Generated Content and New Projects in Emerging Economies
- EC Trade Negotiators and Industry Discuss How to ‘Re-Educate’ Public About Intellectual Property Rights (talk about employment)
- Witnesses at U.S. Trade Hearing Offer Opinions (and Warnings) on Intellectual Property in Upcoming Negotiations with the EU